PulmoCORE Panel 6

pulmoCORE Panel 6 offers testing of various genes that are associated with non-small cell lung cancer. The panel looks for genetic mutations in EGFR, ALK, and ROS-1 genes. The presence of these specific mutations in non-small cell lung cancer (NSCLC) indicates sensitivity or resistance to certain therapies. Apart from these genes, this panel also uses PD - L1 (SP263 Ventana), a predictive assay that identifies patients who are most likely to respond to specific therapies, and to formulate timely diagnostic decisions and therapeutic choices. This panel provides important information that can guide treatment decisions in NSCLC patients and helps in identifying patients who may benefit from treatment with medicines including Crizotininb, Ceritinib, and Alectinib. 

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.